Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in locally advanced or metastatic adenoid cystic carcinoma (EGFR-positive)
2006-001694-23Phase 2Completed
- Sponsor
- National Institute of Oncology
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in adenoid cystic carcinoma (ACC), sponsored by National Institute of Oncology. Primary endpoints: Time to progression and Clinical response rate. Started May 2006; status: completed.
02
Drugs
cetuximab
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on 2006-001694-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001694-23.